Article History
Accepted: 19 February 2021
First Online: 2 April 2021
Declarations
:
: No sources of funding were used to conduct this study or prepare this manuscript.
: Mark S. Freedman has received research or educational grants and consultation fees from Sanofi-Genzyme Canada, Hoffmann-La Roche, and EMD Inc. (Canada), Actelion (Janssen/J&J), Alexion, Biogen Idec, Celgene (BMS), Merck Serono, Novartis, and Teva Canada Innovation; is a member of a company advisory board, board of directors, or other similar group for Actelion (Janssen/J&J), Alexion, Atara Biotherapeutics, Bayer Healthcare, Biogen Idec, Celgene (BMS), Clene Nanomedicine, GRI Bio, Hoffman-La Roche, Magenta Therapeutics, Merck Serono, MedDay, Novartis, Sanofi-Genzyme, and Teva Canada Innovation; and has participated in a company-sponsored speaker’s bureau for Sanofi-Genzyme and EMD Serono. Reshmi Roy and Alaa A. Alotaibi have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed equally to the conception of this work, the interpretation of the literature, and the drafting of the manuscript. The original version of the article was written by Alaa A. Alotaibi and was further edited and expanded upon by Reshmi Roy, who submitted the final draft of the article. All versions were reviewed with Mark S. Freedman. All authors critically revised the review and approved the final manuscript for publication.